251 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
Get Rid of 5 Toxic Stocks or Sell Short for Profit http://www.zacks.com/stock/news/292854/get-rid-of-5-toxic-stocks-or-sell-short-for-profit?cid=CS-ZC-FT-292854 Feb 19, 2018 - Overblown toxic stocks are generally susceptible to outside shocks and are loaded with a huge amount of debt.
Here's Why Calithera Biosciences, Inc. Rose as Much as 25.2% Today https://www.fool.com/investing/2018/02/16/heres-why-calithera-biosciences-inc-rose-as-much-a.aspx?source=iedfolrf0000001 Feb 16, 2018 - The tiny pharma stock received an upgrade from a prominent analyst.
Incyte (INCY) CEO Hervé Hoppenot on Q4 2017 Results - Earnings Call Transcript https://seekingalpha.com/article/4147327-incyte-incy-ceo-herve-hoppenot-q4-2017-results-earnings-call-transcript?source=feed_sector_healthcare Feb 15, 2018 -
Incyte (INCY) Beats on Q4 Revenues on Strong Jakafi Sales http://www.zacks.com/stock/news/292651/incyte-incy-beats-on-q4-revenues-on-strong-jakafi-sales?cid=CS-ZC-FT-292651 Feb 15, 2018 - Incyte (INCY) beat on revenues in the fourth quarter driven by an increase in Jakafi sales. The guidance for 2018 was also encouraging.
Incyte (INCY) Beats on Sales in Q4 http://www.zacks.com/stock/news/292564/incyte-incy-beats-on-sales-in-q4?cid=CS-ZC--292564 Feb 15, 2018 - Incyte (INCY) beat on sales in the fourth quarter driven by growth in Jakafi sales.
Is Agenus Inc. a Buy? https://www.fool.com/investing/2018/02/13/is-agenus-inc-a-buy.aspx?source=iedfolrf0000001 Feb 13, 2018 - This small biotech stock is a high-risk but potentially high-reward proposition.
Can Jakafi Performance Drive Incyte's (INCY) Q4 Earnings? http://www.zacks.com/stock/news/292134/can-jakafi-performance-drive-incytes-incy-q4-earnings?cid=CS-ZC-FT-292134 Feb 12, 2018 - Growth in Jakafi sales are likely to help Incyte (INCY) to beat on earnings in Q4.
Will Prothena (PRTA) Disappoint Investors in Q4 Earnings? http://www.zacks.com/stock/news/291932/will-prothena-prta-disappoint-investors-in-q4-earnings?cid=CS-ZC-FT-291932 Feb 09, 2018 - Although Prothena's (PRTA) track record is good, the company is unlikely to beat estimates in the current quarter given the unfavorable rank and Earnings ESP.
5 Biotech Stocks Set to Trump Estimates This Earnings Season http://www.zacks.com/stock/news/291539/5-biotech-stocks-set-to-trump-estimates-this-earnings-season?cid=CS-ZC-FT-291539 Feb 06, 2018 - Total earnings for the medical sector are up 16.9% from the same period last year on 8.5% higher revenues so far.
AstraZeneca (AZN) Beats on Q4 Earnings, Guides for 2018 http://www.zacks.com/stock/news/291170/astrazeneca-azn-beats-on-q4-earnings-guides-for-2018?cid=CS-ZC-FT-291170 Feb 02, 2018 - AstraZeneca (AZN) beats earnings estimates in fourth quarter on higher product revenues.

Pages: 1...89101112131415161718...26

<<<Page 13>